These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8671675

  • 1. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
    Yu WG, Yamamoto N, Takenaka H, Mu J, Tai XG, Zou JP, Ogawa M, Tsutsui T, Wijesuriya R, Yoshida R, Herrmann S, Fujiwara H, Hamaoka T.
    Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
    [Abstract] [Full Text] [Related]

  • 2. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
    Ogawa M, Yu WG, Umehara K, Iwasaki M, Wijesuriya R, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T.
    Cancer Res; 1998 Jun 01; 58(11):2426-32. PubMed ID: 9622084
    [Abstract] [Full Text] [Related]

  • 3. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.
    Ogawa M, Tsutsui T, Zou JP, Mu J, Wijesuriya R, Yu WG, Herrmann S, Kubo T, Fujiwara H, Hamaoka T.
    Cancer Res; 1997 Jun 01; 57(11):2216-22. PubMed ID: 9187124
    [Abstract] [Full Text] [Related]

  • 4. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
    Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, Hamaoka T.
    J Leukoc Biol; 1997 Oct 01; 62(4):450-7. PubMed ID: 9335314
    [Abstract] [Full Text] [Related]

  • 5. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells.
    Tsutsui T, Mu J, Ogawa M, Yu WG, Suda T, Nagaga S, Saji F, Murata Y, Fujiwara H, Hamaoka T.
    J Immunol; 1997 Sep 15; 159(6):2599-605. PubMed ID: 9300678
    [Abstract] [Full Text] [Related]

  • 6. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models.
    Iwasaki M, Yu WG, Uekusa Y, Nakajima C, Yang YF, Gao P, Wijesuriya R, Fujiwara H, Hamaoka T.
    Int Immunol; 2000 May 15; 12(5):701-9. PubMed ID: 10784616
    [Abstract] [Full Text] [Related]

  • 7. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression.
    Ogawa M, Umehara K, Yu WG, Uekusa Y, Nakajima C, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T.
    Cancer Res; 1999 Apr 01; 59(7):1531-8. PubMed ID: 10197625
    [Abstract] [Full Text] [Related]

  • 8. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice.
    Uekusa Y, Yu WG, Mukai T, Gao P, Yamaguchi N, Murai M, Matsushima K, Obika S, Imanishi T, Higashibata Y, Nomura S, Kitamura Y, Fujiwara H, Hamaoka T.
    Cancer Res; 2002 Jul 01; 62(13):3751-8. PubMed ID: 12097285
    [Abstract] [Full Text] [Related]

  • 9. The anti-tumor effects of IL-12 involve enhanced IFN-gamma production by anti-tumor T cells, their accumulation to tumor sites and in situ IFN-gamma production.
    Fujiwara H, Hamaoka T.
    Leukemia; 1997 Apr 01; 11 Suppl 3():570-1. PubMed ID: 9209457
    [Abstract] [Full Text] [Related]

  • 10. Antitumor and antimetastatic effects of interleukin 12.
    Fujiwara H, Hamaoka T.
    Cancer Chemother Pharmacol; 1996 Apr 01; 38 Suppl():S22-6. PubMed ID: 8765411
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10.
    Sun H, Gutierrez P, Jackson MJ, Kundu N, Fulton AM.
    J Immunother; 2000 Apr 01; 23(2):208-14. PubMed ID: 10746547
    [Abstract] [Full Text] [Related]

  • 13. The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-gamma-involving host-tumor interaction.
    Uekusa Y, Ogawa M, Gao P, Iwasaki M, Ono S, Tsujimura T, Nakazawa M, Sakuda M, Clancy B, Fujiwara H, Hamaoka T.
    Int J Oncol; 2000 Apr 01; 16(4):805-14. PubMed ID: 10717251
    [Abstract] [Full Text] [Related]

  • 14. The mechanism of interferon-gamma induced anti Toxoplasma gondii by indoleamine 2,3-dioxygenase and/or inducible nitric oxide synthase vary among tissues.
    Fujigaki S, Takemura M, Hamakawa H, Seishima M, Saito K.
    Adv Exp Med Biol; 2003 Apr 01; 527():97-103. PubMed ID: 15206721
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase.
    Fujigaki S, Saito K, Takemura M, Maekawa N, Yamada Y, Wada H, Seishima M.
    Infect Immun; 2002 Feb 01; 70(2):779-86. PubMed ID: 11796611
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
    Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai XG, Niwa O, Tsujimura T, Sato B, Terano H, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1996 Sep 01; 87(9):963-71. PubMed ID: 8878460
    [Abstract] [Full Text] [Related]

  • 18. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo.
    Burke F, Knowles RG, East N, Balkwill FR.
    Int J Cancer; 1995 Jan 03; 60(1):115-22. PubMed ID: 7814143
    [Abstract] [Full Text] [Related]

  • 19. Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.
    Li XF, Takiuchi H, Zou JP, Katagiri T, Yamamoto N, Nagata T, Ono S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1993 Mar 03; 84(3):315-25. PubMed ID: 8098027
    [Abstract] [Full Text] [Related]

  • 20. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 03; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.